Related Experiment Video
Updated: Jul 5, 2026

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
Published on: December 7, 2013
Wnt5a is expressed in murine and human atherosclerotic lesions
Mark A Christman1, Douglas J Goetz, Eric Dickerson
1Department of Chemical and Biomolecular Engineering, Ohio University, Columbus, Ohio, USA.
Abstract:
Atherosclerosis is an inflammatory disease involving the accumulation of macrophages in the intima. Wnt5a is a noncanonical member of the Wnt family of secreted glycoproteins. Recently, human macrophages have been shown to express Wnt5a upon stimulation with bacterial pathogens in vitro and in granulomatous lesions in the lung of Mycobacterium tuberculosis-infected patients. Wnt5a expression has also been liked to Toll-like receptor-4 (TLR-4), an innate immune receptor implicated in atherosclerosis. These observations, along with the fact that Wnt5a is involved in cell migration and proliferation, led us to postulate that Wnt5a plays a role in atherosclerosis. To investigate this hypothesis, we characterized Wnt5a expression in murine and human atherosclerotic lesions. Tissue sections derived from the aortic sinus to the aortic arch of apolipoprotein E-deficient mice and sections derived from the carotid arteries of patients undergoing endarterectomy were subjected to immunohistochemical analysis. All samples were found to be positive for Wnt5a with predominant staining in the areas of macrophage accumulation within the intima. In parallel, we probed for the presence of TLR-4 and found coincident TLR-4 and Wnt5a expression. For both the Wnt5a and TLR-4 staining, consecutive tissue sections treated with an isotype- and species-matched Ig served as a negative control and exhibited little, if any, reactivity. Quantitative RT-PCR revealed that Wnt5a mRNA expression in RAW264.7 murine macrophages can be induced by stimulation with LPS, a known ligand for TLR-4. Combined, these findings demonstrate for the first time Wnt5a expression in human and murine atherosclerotic lesions and suggest that cross talk between TLR-4 and Wnt5a is operative in atherosclerosis.
Insights
Wnt5a is expressed in atherosclerotic lesions and may play a role in this inflammatory disease. Its expression is linked to Toll-like receptor-4 (TLR-4), suggesting a potential interaction in atherosclerosis.
Area of Science:
- Immunology
- Cardiovascular Biology
- Molecular Medicine
Background:
- Atherosclerosis is an inflammatory condition characterized by macrophage accumulation.
- Wnt5a, a secreted glycoprotein, is expressed by macrophages and linked to Toll-like receptor-4 (TLR-4).
- Wnt5a's known roles in cell migration and proliferation prompted investigation into its function in atherosclerosis.
Purpose of the Study:
- To investigate the role of Wnt5a in atherosclerosis.
- To characterize Wnt5a expression in human and murine atherosclerotic lesions.
- To explore the relationship between Wnt5a and TLR-4 in the context of atherosclerosis.
Main Methods:
- Immunohistochemical analysis of Wnt5a and TLR-4 expression in atherosclerotic lesions from apolipoprotein E-deficient mice and human carotid arteries.
- Quantitative RT-PCR to assess Wnt5a mRNA expression in RAW264.7 murine macrophages stimulated with LPS (a TLR-4 ligand).
Main Results:
- Wnt5a was detected in both murine and human atherosclerotic lesions, primarily in areas of macrophage accumulation within the intima.
- TLR-4 expression was coincident with Wnt5a staining.
- LPS stimulation induced Wnt5a mRNA expression in macrophages, indicating TLR-4 mediated regulation.
Conclusions:
- Wnt5a is expressed in human and murine atherosclerotic lesions.
- A cross-talk between TLR-4 and Wnt5a is suggested to be active in atherosclerosis.
- Wnt5a represents a potential target for therapeutic intervention in atherosclerosis.
Related Concept Videos
Atherosclerosis I: Introduction
Canonical Wnt Signaling Pathway
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
Non-Canonical Wnt Signaling Pathways
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

